Meytes D, Katz D, Ramot B
Isr J Med Sci. 1976 Jun;12(6):534-42.
Thirty-nine patients with myelofibrosis and myeloid metaplasia were diagnosed and followed during the period 1955-74. Twenty-eight suffered from agnogenic myeloid metaplasia and 11 from myeloid metaplasia following polycythemia vera. In an attempt to compare the two groups and to define prognostic guidelines, an analysis of survival with respect to various clinical parameters was made. The median survival time of patients with agnogenic myeloid metaplasia was seven years as opposed to only 28 months for the poltpolycythemic group. Older age at diagnosis, a large spleen, or its rapid enlargement, anemia and leukocytosis, but not thrombocytopenia, had a marked negative effect on survival. The clinical condition of most patients was remarkably stable during the entire course of their disease. If a significant drop in hemoglobin occurred, it was sudden, and caused by gastrointestinal hemorrhage or the development of acute leukemia. No demonstrable effect of therapy on survival was found.
1955年至1974年期间，对39例骨髓纤维化和髓外化生患者进行了诊断和随访。其中28例为特发性髓外化生，11例为真性红细胞增多症后髓外化生。为了比较这两组患者并确定预后指标，对各种临床参数的生存情况进行了分析。特发性髓外化生患者的中位生存时间为7年，而真性红细胞增多症组仅为28个月。诊断时年龄较大、脾脏肿大或迅速增大、贫血和白细胞增多，但血小板减少对生存没有显著负面影响，对生存有明显的负面影响。大多数患者在整个病程中临床状况明显稳定。如果血红蛋白显著下降，则是突然发生的，原因是胃肠道出血或急性白血病的发生。未发现治疗对生存有明显影响。
